Acquires Theorem Clinical Research - Clinical Supplies in Frankfurt, Germany
December 5, 2016 - Clinical Supplies Management ("CSM"), a Great Point Partners ("GPP") portfolio company, today announced it has acquired the assets of Theorem Clinical Research - Clinical Supplies ("TCS"). TCS was previously a subsidiary of Chiltern International and focuses on clinical trial drug packaging, labeling, storage, reconciliation, and distribution for pharmaceutical trials across Europe. With the acquisition of TCS, CSM has broadened its geographic coverage with facilities in the United States and Europe to better serve the needs of its global clients.
"We are very excited to welcome the experienced team from TCS into the CSM family. The combination of two specialized clinical supply management companies with 20 year histories of outstanding service and quality creates an exciting solution for the pharmaceutical and biotech industry," said Scott Houlton, CSM Chief Executive Officer. "The expansion into Europe has been a key customer request for CSM and TCS is an excellent addition. TCS operates out of a new facility strategically located in Frankfurt, Germany and currently services a multinational customer base. I look forward to working with Rüdiger and his team to continue to grow the business."
Rüdiger Weber, Executive Director at TCS commented, "We are very pleased to be joining CSM, which is exclusively dedicated to clinical supplies. The two companies have built strong reputations for service and delivery and I believe we can offer a preferred solution to customers who are looking for an innovative and flexible partner with global scale."
The addition of TCS to CSM adds full service clinical packaging and logistics in Europe and broadens the customer base. TCS will operate as a subsidiary of Clinical Supplies Management Holdings, Inc. under the name CSM Clinical Supplies Management Europe, GmbH.
About Clinical Supplies Management
Since 1997, CSM has been providing innovative solutions to meet the complex clinical supply challenges pharmaceutical and biotechnology companies face. CSM manages the clinical supply chain for hundreds of satisfied clients worldwide, providing services that keep clinical trials on time and on budget. CSM offers a full suite of cGMP-compliant services, continually delivering quality supplies to clinical sites and patients around the world. From Phase I all the way to large Phase III projects, CSM has the flexibility to meet the needs of all drug trials regardless of size and scope. CSM's customer-centric approach, revolutionary processes, and state-of-the-art clinical services increase efficiencies, reduce costs, and improve outcomes for clinical trials. Some of CSM's clinical services include packaging and labeling, storage and global distribution, controlled drug services, clinical supplies consulting, as well as returns, reconciliation, and destruction. Reach CSM at 866-487-3276 or www.csmondemand.com.
About Great Point Partners
Great Point Partners ("GPP"), founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with approximately $1 billion of equity capital under management and 28 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new private equity investments from GPP II, which has closed on $215 million. Great Point manages capital in private (GPP I, $156 million and GPP II) and public (BioMedical Value Fund, approximately $525 million) equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 growing health care companies. The private equity funds invest across all sectors of the health care industry with particular emphasis on biopharmaceutical services and supplies, services, outsourcing, pharmaceutical infrastructure, and information technology enabled businesses. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies. Reach Great Point at 203-971-3300 or www.gppfunds.com.